Kintor Pharmaceutical Limited announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 (pyrilutamide) in China for the treatment of acne vulgaris on 14 October 2022. The phase II clinical trial is a randomized, double-blind, placebo-controlled, multi-regional clinical study to evaluate the safety and efficacy of KX-826 (gel) in patients with mild to moderate acne vulgaris. The primary endpoint is the treatment success rate in each group at the end of week 12 (according to the 5-point Investigator Global Assessment (IGA) scale, subjects whose IGA scale decreases by not less than two levels to 0-1 defined as success).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.22 HKD | 0.00% | +0.83% | -25.15% |
04/06 | Kintor Pharma Receives Standard Cosmetic Ingredient Name for KX-826 Product | MT |
24/05 | Kintor Pharmaceutical's Androgenic Alopecia Drug Gets Regulatory Nod; Share Prices Shoot 10% | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.15% | 68.62M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+1.16% | 22.78B | |
-10.60% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- 9939 Stock
- News Kintor Pharmaceutical Limited
- Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX 826 for Acne Vulgaris in China